Oxidative Damage May Lead to Neurocognitive Decline
the Cancer Therapy Advisor take:
Oxidative damage may contribute to chemotherapy-associated neurocognitive decline in survivors of childhood acute lymphoblastic leukemia (ALL), according to a recent study published online ahead of print in the Journal of Clinical Oncology.
Researchers led by Peter Cole, MD, of the Albert Einstein College of Medicine examined genomic DNA that was isolated from bone marrow in 350 pediatric leukemia survivors.
“This study was conducted to test whether interpatient variability in neurocognitive outcomes can be explained by polymorphisms in candidate genes conferring susceptibility to neurocognitive decline,” they stated.
These polymorphisms were selected based on prior literature. Multivariable logistic regression models were used to estimate the association between genotype and neurocognitive outcomes.
They found that inferior cognitive or behavioral outcomes were associated with polymorphisms in three genes (NOS3, SLCO2A1, and COMT) that were related to oxidative stress or neuroinflammation.
Oxidative damage may contribute to chemotherapy-associated neurocognitive decline in survivors of childhood ALL.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer